Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled and is being dosed...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces today that the independent safety committee (IDMC) for the phase II study...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company has been awarded the International Diamond Prize for...
Read moreJuly – September Financial summary Net turnover amounted to SEK 1.7 (3.0) million. The loss before interest, tax, depreciation and amortization...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) reports today that the ninth and final patient was recruited to the phase...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that a poster entitled “MIV-818 stimulates an anti-tumor immune response in...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled in a phase I...
Read moreApril – JuneSignificant events during the quarter Selective effect signal on liver cancer tissue in phase Ia study with MIV-818. The...
Read moreStockholm, Sweden – Medivir AB (Nasdaq, Stockholm: MVIR) today announces the results of an analysis of data from the first six...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the 2019 BIO International Convention in...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in...
Read moreStockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the company will participate at the Redeye Pre-ASCO Seminar in Stockholm....
Read more